Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. 21 Μαρ 2022 · This study aimed to identify specific symptom clusters associated with a positive SARS-CoV-2 nasopharyngeal swab and recognized 4 symptom clusters, that is, cluster 1 was characterized by flulike symptoms (rhinitis, pharyngodynia, cough, fever, myalgia, headache, gastrointestinal symptoms, anosmia/ageusia), in 40.6% of the recruited individuals ...

    • PubMed

      Only 26.1% (95% CI, 24.1%-28.2%) of infected individuals...

  2. 4 Νοε 2022 · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains asymptomatic in 33% to 90% of older adults depending on their immune status from prior infection, vaccination, and circulating strain.

  3. 13 Οκτ 2020 · The Centers for Disease Control and Prevention (CDC) report that symptoms of COVID-19 typically appear 2–14 days after exposure to the severe acute respiratory syndrome coronavirus 2...

  4. 9 Αυγ 2021 · It was estimated that 80% of the infected patients with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention...

  5. 10 Μαρ 2021 · Key Points. Question What is the association of age with the likelihood of developing respiratory symptoms or fever greater than or equal to 37.5 °C and the association of age with the likelihood of progressing to critical disease after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection?. Findings In this cohort study, 5484 quarantined case contacts were monitored daily ...

  6. 17 Ιουλ 2023 · Individuals with SARS-CoV-2 infection can develop symptoms that persist well beyond the acute phase of COVID-19 or emerge after the acute phase, lasting for weeks or months after the initial acute illness.

  7. 1 Μαρ 2021 · Only 26.1% (95% CI, 24.1%-28.2%) of infected individuals younger than 60 years developed respiratory symptoms or fever greater than or equal to 37.5 °C; among infected participants older than 60 years, 6.6% (95% CI, 5.1%-8.3%) developed critical disease.